Navigation Links
Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Mounting Claims Involving Risperdal Gynecomastia Allegations in Pennsylvania Litigation
Date:11/13/2013

New York, New York (PRWEB) November 13, 2013

At least 250 Risperdal lawsuits (http://www.therisperdallawsuit.com/), many involving allegations that the use of the antipsychotic drug caused boys to develop gynecomastia, or male breast growth, are currently pending in a litigation underway in Pennsylvania’s Philadelphia Court of Common Pleas, Bernstein Liebhard LLP reports. According to court documents, while a few of the cases involving Risperdal gynecomastia allegations filed in the litigation have settled, the majority of such claims remain unresolved. (Risperdal Litigation, case number 100300296)

“Our Firm is following this litigation very closely, as we have heard from numerous individuals concerned about the alleged connection between the use of Risperdal and male breast growth,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free Risperdal lawsuit consultations to any individual who may have developed gynecomastia due to Risperdal.

Risperdal Lawsuits

Known as an atypical antipsychotic, Risperdal is currently approved for the treatment of schizophrenia in adults and adolescents, as well as bipolar disorder in adults and children ages 10-to-17. Risperdal is also approved to treat irritability in children (5-to-16 years of age) with autistic disorder.* There are also indications that use of Risperdal to treat ADHD is also on the rise, though it’s not been approved for this purpose.**

On November 4th, the U.S. Department of Justice announced that it had reached an agreement with Johnson & Johnson and its Janssen Pharmaceuticals Inc. unit by which the companies will pay $2.2 billion to settle a government probe into the marketing of some of their drugs, including Risperdal. According to a press release issued by the Justice Department, the settlement includes $4.85 million in criminal fines, and $1.72 billion in civil penalties. Among other things, the agreement resolves charges that Johnson & Johnson misbranded Risperdal and promoted off-label use of the drug for children, elderly nursing home patients, and those with mental disabilities.

Court records indicate that in October 2012, Johnson & Johnson and Janssen agreed to settle five claims involving Risperdal and gynecomastia that had been filed in the Pennsylvania litigation. Among other things, the lawsuits alleged that the companies knew use of the drug could lead to male breast development, and that its sales reps were trained to downplay this potential Risperdal side effect. The Plaintiffs also alleged that Risperdal was illegally marketed for use in children.***

Alleged victims of Risperdal and male breast growth may be entitled to compensation for medical bills, lost wages, pain and suffering and more. Learn More about Risperdal and gynecomastia at Bernstein Liebhard LLP’s website. For a free case review, please contact the Firm by calling 800-511-5092.

*accessdata.fda.gov/drugsatfda_docs/label/2009/020272s056,020588s044,021346s033,021444s03lbl.pdf, Risperdal Prescribing Information, FDA, 2009
**health.usnews.com/health-news/news/articles/2012/08/07/more-kids-taking-antipsychotics-for-adhd-study, U.S. News & World Report, August 7, 2012
***bloomberg.com/news/2012-10-04/johnson-johnson-agrees-to-settle-five-rispersal-suits.html, Bloomberg.com, October 4, 2012

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com

http://www.therisperdallawsuit.com/
https://plus.google.com/115936073311125306742?rel=author

Read the full story at http://www.prweb.com/releases/risperdal-lawsuit/risperdal-gynecomastia/prweb11330758.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Risperdal Lawsuit News: Rottenstein Law Group LLP Comments on $2 Billion Risperdal Settlement Report
2. J&J to Pay $2.2B to Settle Allegations Over Its Marketing of Risperdal; Parker Waichman LLP Applauds Efforts of Whistleblowers in Helping Compel Resolution
3. Risperdal Lawsuit News: Johnson & Johnson To Pay Over $2.2 Billion In Risperdal and Invega Settlement Draws Comment From Wright & Schulte LLC
4. Risperdal Lawsuits: $2.2 Billion Settlement Between Federal Government, Johnson & Johnson Over Alleged Illegal Marketing of Risperdal, Other Medications
5. Risperdal Lawsuit News: Bernstein Liebhard LLP Comments on Settlement in Risperdal Marketing Investigation
6. New Risperdal Lawsuit Filed in Pennsylvania Litigation; Alleges Male Breast Growth Injuries Caused by Anti-Psychotic Medication, Bernstein Liebhard LLP Reports
7. Bernstein Liebhard LLP Investigating Risperdal Lawsuits on Behalf of Victims of Male Breast Growth Allegedly Caused by Risperdal
8. The Consumer Justice Foundation Launches RisperdalLaw.com, an Informational Web Site Dealing with Alleged Risperdal Side Effects Including Gynecomastia
9. Parker Waichman LLP Commends Arkansas Attorney General for Backing Fine Against Johnson & Johnson over Risperdal Off-Label Marketing Allegations
10. Lipitor Lawsuits Continue to Mount, as Bernstein Liebhard LLP Notes Filing of New Claim Alleging an Association Between Lipitor and Diabetes
11. Pradaxa Lawsuits Continue to Mount, With Filing of New Pradaxa Wrongful Death Claim in Pennsylvania by Wright & Schulte LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... ... Advanced Surgical, Inc. is thrilled to offer the recently FDA-approved Obalon Balloon System ... procedure adds to SkyLex Advanced Surgical’s already comprehensive list of weight-loss services. ...
(Date:3/28/2017)... ... , ... Oily skin is a common and unwelcomed occurrence in people of all ages, genders ... offer to the discussion of dealing with excess skin oil. “Oily skin is a challenge ... that can help remove the oily shine while keeping the skin fresh and clean,” says ...
(Date:3/27/2017)... ... March 27, 2017 , ... New patients who have ... sleep apnea treatment, with or without a referral. Sleep apnea is often left untreated ... daytime sleepiness, morning headaches and chronic snoring. , Dr. Braasch seeks to raise ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... gain site attention and engagement over the household brands of Top-20 pharma by ... will discuss how partnering with the right outsourcing payments provider can provide the ...
(Date:3/27/2017)... ... 27, 2017 , ... Adding to its expanding portfolio of ... and NEJM Journal Watch, announces the release of NEJM Knowledge+ Pediatrics Board ... of pediatricians from leading medical centers. The content was then reviewed and approved ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... Elysium Health joins major pharmaceutical ... Cambridge academic scientists through ... Milner Therapeutics Institute today announces Elysium Health as a partner ... investment for collaborative projects with academic researchers in ... the first major research investment outside the U.S. for the ...
(Date:3/27/2017)... 2017 Therapix Biosciences Ltd. ... in the development of cannabinoid-based drugs, today announced ... the United States of 2,000,000 ... ordinary shares of the Company, at a price ... granted the underwriters a 45-day over-allotment option to ...
(Date:3/27/2017)... VANCOUVER, British Columbia , March 27, 2017 /PRNewswire/ ... of Directors has appointed William "Bill" Dubiel as President ... Dubiel was also elected to the Board of Directors ... serve as the Executive Chairman of LightIntegra. ... become LightIntegra,s next President and Chief Executive Officer. We,ve ...
Breaking Medicine Technology: